Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status

Overview

In this study, the investigators are attempting to evaluate the influence of socio-economic factors on the functional recovery (physical and psychological) of patients who developed ARDS after a COVID-19 infection, with the aim of offering personalized medical and social follow-up and support measures in order to avoid medium- and long-term complications, which can result in handicaps, reduced quality of life, and a higher risk of death.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 20, 2022

Interventions

  • Other: Paraclinical examination
    • Respiratory functional tests
  • Other: Clinical Examination
    • Clinical Examination
  • Other: Semi-directive interview
    • By phone
  • Other: quality of life questionnaires
    • SF36, VSRQ, IESR, HADS

Arms, Groups and Cohorts

  • Patient
    • Patient hospitalized in ICU for PCR-proven SARS-COV-2 infection

Clinical Trial Outcome Measures

Primary Measures

  • Respiratory sequelae 6 months after resuscitation.
    • Time Frame: Through study completion, an average of 6 months
    • Defined by the presence of at least one of the following : An alteration of the alveolar-capillary diffusion of CO <80% of the predicted normal values And/or a forced vital capacity <80% of predicted normal values and/or O2 desaturation in the 6-minute walk test And/or pulmonary parenchymatous disease with fibrosis in tomodensitometry.

Participating in This Clinical Trial

Inclusion Criteria

  • Inpatient in ICU for PCR-proven SARS-VOC-2 infection regardless of specimen type – Patient who received a chest CT scan in the initial phase of management (either just before or during hospitalization in the intensive care unit) – Patient who has received invasive or non-invasive ventilatory support, or humidified and heated high-flow oxygen (HFO). – ARDS meeting the criteria of the 2012 Berlin definition. For patients who have received only HFO, a flow rate at least equal to 50L/minute with a FiO2 strictly greater than 50% with a PaO2/FiO2 ratio less than or equal to 200 will be required for inclusion. – Patient who gave oral consent after being informed about the conduct of this study. Exclusion Criteria:

  • Patient with limited autonomy prior to hospitalization in limited intensive care unit: walking distance of less than 50 meters, WHO classification status 3 and 4. – Patient with a history of chronic respiratory failure as defined by the use of long-term oxygen therapy or non-invasive home ventilation, excluding patients with SAS and/or hypoventilation obesity syndrome. – Patient with a history of central or peripheral neurological conditions limiting the patient's motor autonomy and the performance on gait tests or Pulmonary function Tests – Patient refusing to participate – Patient < 18 years of age – Patient not affiliated or not benefiting from national health insurance – Patient under guardianship, curatorship or protected adult – Patient unable to understand and consent to the research protocol SECONDARY EXCLUSION CRITERIA – Patient not showing up for visit at M6 – Patients who have not had all the examinations necessary to evaluate the main endpoint (Spirometry, DLCO, TM6 and CT)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire Dijon
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.